Metacrine

$9.04
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.12 (+1.35%) As of 8:57 PM UTC today

Why Robinhood?

You can buy or sell Metacrine and other stocks, options, and ETFs commission-free!

About MTCR

Metacrine, Inc. Common Stock, also called Metacrine, is a clinical-stage biopharmaceutical company that engages in the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. Its farnesoid X receptor, or FXR, is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA. The listed name for MTCR is Metacrine, Inc. Common Stock.

CEO
Preston S. Klassen
Employees
—
Headquarters
San Diego, California
Founded
2015
Market Cap
220.43M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
35.70K
High Today
$9.06
Low Today
$8.75
Open Price
$8.92
Volume
21.53K
52 Week High
$16.19
52 Week Low
$7.64

Collections

MTCR Earnings

-$1.41
-$0.94
-$0.47
$0.00
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 15, Pre-Market

You May Also Like

ZROZ
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure